US 11,952,389 B2
Benzodiazepine derivatives as RSV inhibitors
Brian C. Shook, Holliston, MA (US); In Jong Kim, Lexington, MA (US); Thomas P. Blaisdell, Watertown, MA (US); Jianming Yu, Plainsboro, NJ (US); Joseph D. Panarese, Newton, MA (US); and Yat Sun Or, Waltham, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed on May 3, 2022, as Appl. No. 17/735,258.
Application 17/735,258 is a continuation of application No. 17/081,289, filed on Oct. 27, 2020, granted, now 11,390,631.
Application 17/081,289 is a continuation of application No. 16/739,312, filed on Jan. 10, 2020, granted, now 10,865,215, issued on Dec. 15, 2020.
Application 16/739,312 is a continuation of application No. 15/914,016, filed on Mar. 7, 2018, granted, now 10,570,153, issued on Feb. 25, 2020.
Application 15/914,016 is a continuation of application No. 15/216,119, filed on Jul. 21, 2016, granted, now 9,957,281, issued on May 1, 2018.
Claims priority of provisional application 62/195,648, filed on Jul. 22, 2015.
Claims priority of provisional application 62/335,227, filed on May 12, 2016.
Prior Publication US 2023/0087410 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 235/24 (2006.01); A61K 31/5513 (2006.01); A61K 31/56 (2006.01); A61K 31/58 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); A61P 31/16 (2006.01); C07D 243/16 (2006.01); C07D 403/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/08 (2006.01); C07D 491/048 (2006.01); C07D 495/04 (2006.01); C07D 498/08 (2006.01); C07D 513/04 (2006.01)
CPC C07D 513/04 (2013.01) [A61K 31/5513 (2013.01); A61K 31/56 (2013.01); A61K 31/58 (2013.01); A61K 45/06 (2013.01); C07D 243/16 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/08 (2013.01); C07D 491/048 (2013.01); C07D 495/04 (2013.01); C07D 498/08 (2013.01)] 9 Claims
 
1. A compound represented by the formula

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
R4 is

OG Complex Work Unit Chemistry
and R4 is substituted with at least one substituent selected from the group consisting of CH3, CN, fluoro, chloro, CH3O—, CH3C(O)—, CH3OCH2—, CH3OCH2CH2O—, —CF3, CF3O—

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry